Zacks Investment Research
11 Jun 2026, 16:51 UTC · 2h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Top 2 movers · tap to explore
What the story claims
3 claims · each scored for market impact
Puma Biotechnology raised its 2026 total revenue guidance to a range of $222-$229 million, up from the previous $214-$221 million. — Upward revisions to full-year revenue guidance typically signal strength and are a primary driver for share price appreciation.
+0.60First-quarter 2026 Nerlynx sales of $42 million exceeded management's guidance range of $36-$39 million. — Beating internal guidance indicates stronger-than-expected product demand, supporting a bullish outlook for the company's sole marketed product.
+0.40Puma Biotechnology shares have rallied 19.4% over the past three months, outperforming its industry which declined 6.9%. — Strong relative strength suggests positive investor sentiment and momentum, though it is a trailing indicator rather than a fundamental catalyst.
+0.20Which stocks this story touches
Continue reading
6 related stories
The company raised its 2026 revenue outlook and experienced strong stock growth due to higher-than-expected Nerlynx sales.
Mentioned only as a provider of a therapy that patients receive prior to using Puma Biotechnology's product.
Go deeper
You just saw which tickers this one story hits. A free account turns that into a standing screen: the movers delivered on schedule, before the chart catches up.
On this page · free
In the platform
Free account, 30 seconds. No credit card. Covers all 10 tickers this story moves.
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Screener bridge
Catch the names this kind of story moves — before the chart does.
Get the full NIS Momentum results every Friday at 4PM ET — free via email or Telegram.
Proactive Investors
8h ago
